PE firm Ardian in exclusive talks to buy controlling stake in Unither Pharmaceuticals

Private equity firm Ardian yesterday said that it had entered into exclusive talks with Equistone Partners to buy the controlling stake in medical packaging manufacturer Unither Pharmaceuticals.

Without disclosing the offer price, Ardian said that it will make new investments in the Unither business.

Founded in 1993, Paris-based Unither is a contract manufacturing company focused on a few premeasured dosage forms.

It develops, manufactures, and sells sterile unit dose preparations for pharmaceutical laboratories and generic manufacturers in Europe and internationally.

It offers eye drops, saline solutions, and sterile unit dose asthma drugs using Blow-Fill-Seal technology. The company also manufactures liquid or powder stick-packs and effervescent tablets, as well as drug delivery systems using the transmucosal technology; and provides pharmaceutical development and formulation, analytical validation, ICH stability testing, clinical manufacturing and packaging, quality assurance, and validation/maintenance services.

Unither operates four production sites in France as well as research and development centre, has sales of more than €250 million ($268 million) and employs more than 1,200 people.